Clinical, pathological and molecular characteristics of patients with disease recurrence despite pathologic response to neoadjuvant ipilimumab plus nivolumab in stage III melanoma.

Commun Med (Lond) · 2025 · PMC12484825 · PMID 41028530

Europe PMC DOI

hedged sentence

0.8760

closest p · 17.5× alpha

0.8760

boldest claim

The sentences

a numerical trendp = 0.876not close (p > 0.1)

Neither baseline IFNγ signature nor TMB levels were significantly different between patients with pathologic response and subsequent disease recurrence versus those without, despite a numerical trend towards a lower TMB level in the recurrence group at baseline (median IFNγ 0.2855 versus 0.2034, p = 0.876, and median TMB 346.5 versus 484, p = 0.760, respectively) [Fig. 1b ].

also in 1,012 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.